Multiple studies provide new understanding and treatment approaches for Parkinson’s disease (PD). Research into parkin-deficient neurons reveals mechanisms of seeding-competent α-synuclein aggregates driving pathology. The Michael J. Fox Foundation launched the Targets to Therapies program to accelerate validation of biological targets. Additionally, a novel fusion AI architecture detects PD via speech analysis, and butyrate shows promise in restoring sleep in PD mouse models through BDNF modulation. Clinical trials continue evaluating antibody and cell therapies targeting early-stage disease progression.